ST6GAL1 and prostate carcinoma: To address this gap, we used western blotting and pre-validated sandwich ELISA assays [77] to monitor ST6GAL1 protein levels in VCaP and LNCaP prostate cancer cell line models with acquired resistance to enzalutamide.